SCHEMBL19783154

SCHEMBL19783154

COc1cc(C2CC2)c2nc(Br)sc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.34
RAB9A P51151 8/20 0.34
GRM2 Q14416 1/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33
MAPT P10636 5/20 0.32
SMN1; SMN2 Q16637 6/20 0.32
MEN1 O00255 5/20 0.32
KMT2A Q03164 5/20 0.32
PDK1 Q15118 1/20 0.32
F2RL3 Q96RI0 1/20 0.32
ALDH1A1 P00352 3/20 0.32
HPGD P15428 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
NFKB1 P19838 2/20 0.32
HTT P42858 2/20 0.32
NFKB2 Q00653 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189685 1.00 NPC1 (0.34) NPC1RAB9AGRM2MAOAMAOB
SCHEMBL30189609 0.84 CYP3A4 (0.48) CYP1A2CYP3A4CYP2C19MAPTALDH1A1
SCHEMBL19782548 0.84 CYP3A4 (0.48) CYP1A2CYP3A4CYP2C19MAPTALDH1A1
SCHEMBL19782536 0.76 NSD1 (0.33) MAOAMAOB
SCHEMBL19782939 0.76 F2RL3 (0.43) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL19782620 0.76 F2RL3 (0.45) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL30189854 0.74 LCK (0.48) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL19783358 0.74 F2RL3 (0.44) CYP1A2CYP3A4CYP2C19PDK1F2RL3
SCHEMBL30189743 0.74 F2RL3 (0.44) CYP1A2CYP3A4CYP2C19PDK1F2RL3
SCHEMBL19782618 0.74 F2RL3 (0.44) NPC1RAB9ACYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 NPC1 2639/4885RAB9A 667/4885GRM2 3966/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 NPC1 2194/4885RAB9A 748/4885GRM2 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.